Stockreport

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phase 1 SAD/MAD study thi [Read more]